Advisortrust Partners LLC Invests $1.49 Million in Eli Lilly and Company $LLY

Advisortrust Partners LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 1,388 shares of the company’s stock, valued at approximately $1,491,000. Eli Lilly and Company comprises 0.7% of Advisortrust Partners LLC’s holdings, making the stock its 29th biggest position.

Other large investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $25,000. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $30,000. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $33,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the last quarter. Finally, Dorato Capital Management acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $36,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,098.78 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,182.73. The firm has a 50-day moving average of $1,016.10 and a two-hundred day moving average of $1,017.41. The stock has a market cap of $1.03 trillion, a P/E ratio of 39.03, a PEG ratio of 1.20 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the company posted $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a $1.73 dividend. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s latest quarter showed standout fundamentals, with revenue up 55.5% year over year to $19.80 billion and full-year guidance raised to $82 billion-$85 billion, reinforcing the company’s leadership in GLP-1 drugs like Mounjaro. Prediction: Eli Lilly Will Trade at $1,200 on This Date
• Positive Sentiment: Analysts and market commentators remain bullish, citing Lilly’s rapid earnings growth, heavy manufacturing investment, and ongoing leadership in obesity and diabetes treatments as reasons the stock could keep climbing. Under Dave Ricks, Lilly Is Minting Money on GLP-1 Drugs and Spending It Wisely
• Positive Sentiment: New collaborations around Lilly TuneLab, including partnerships with Charles River and Chai Discovery, expand the company’s AI-driven drug discovery ecosystem and could support longer-term pipeline productivity. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
• Neutral Sentiment: Several articles highlighted ongoing pipeline progress, including completion of trials for retatrutide and mevidalen, which are worth watching but did not include definitive late-stage results. Retatrutide Trial Completion Signals Next Step for Eli Lilly’s Diabetes Pipeline
• Neutral Sentiment: Some commentary framed Lilly as still undervalued relative to its growth narrative and pointed to AI-driven healthcare as another possible upside theme, but these pieces were largely opinion-based rather than new company-specific catalysts. Eli Lilly (LLY) Stock Could Be 24.7% Undervalued on Its Growth Narrative
• Negative Sentiment: LLY also saw a short-term pullback in the prior session, showing that even with strong fundamentals, investors have been taking some profits after the stock’s big run. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: A report that Lilly has begun denying some 340B discounts could create friction with healthcare buyers and adds a potential reimbursement-related overhang. Eli Lilly begins denying 340B discounts

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LLY. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.